In this study, competitive inhibitors of KMT2A could reduce PU.1 expression by inhibiting KMT2A complex, and showed therapeutic effects in bleomycin‐induced pulmonary fibrosis in mice. This evidence concerns the gene KMT2A and pulmonary fibrosis.